Explore the latest in Huntington disease, including advances in understanding its epidemiology, etiology, diagnosis, and management.
This cross-sectional study of 5 European cohort studies determines the prevalence of carriers of intermediate and pathological polyglutamine disease–associated alleles among the general population.
This study uses data from the Track and COHORT studies to examine an approach to planning prediagnosis clinical trials for Huntington disease.
This cross-sectional study investigates the association between brain metabolism and motor scores of patients with early Huntington disease.
This open-label, single-arm study evaluates the safety and explores the efficacy of conversion from tetrabenazine to deutetrabenazine in patients with chorea associated with Huntington disease.
This Teachable Moment describes a case of a man readmitted to the hospital for complications with his ileostomy bag; after magnetic resonance imaging of his brain and appropriate testing, he was diagnosed with Huntington disease.
This case series examines patients with Huntington disease (HD) phenotypes to determine the frequency of HD phenocopies with typical features of HD but without pathological CAG repeat expansions in HTT in an attempt to improve the positive diagnosis rate.
This randomized clinical trial compares the effects of deutetrabenazine vs placebo on chorea among patients with Huntington disease.
This case report describes a white man in his mid to late forties with a history of Huntington disease presented with acute painful left eye vision loss
This cohort study evaluates the use of measures associated with cytosine-adenine-guanine (CAG) expansion that can be determined to identify individuals with CAG expansion before the diagnosis of Huntington disease.
This study concludes that information on the causative events of Huntington disease might help identify biomarkers that could be used to facilitate clinical trials.
Dorsey et al determine the longitudinal change in clinical features among individuals with Huntington disease compared with controls.
Marder et al attempted to determine whether the MeDi modifies the time to clinical onset of Huntington disease (phenoconversion) in premanifest carriers participating in Prospective Huntington at Risk Observational Study (PHAROS) and to examine the effects of body mass index and caloric intake on time to phenoconversion.
We provide an update on the state of translational research in movement disorders, using examples of Huntington disease, Parkinson disease, and dystonia. While substantial progress in our understanding of these disorders has been achieved, development of neuroprotective treatments remains an unrealized goal. Here we highlight some of the emerging research areas that show the most promise for translational research in Huntington disease, Parkinson disease, and dystonia. Aetiology and pathogenesis, biomarker directions, and causal treatment opportunities are discussed for each disease, followed by a brief discussion drawing attention to important translational initiatives.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: